Symbols / CADL Stock $8.16 -5.94% Candel Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
CADL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
Exch · Country NGM · United States
Market Cap 597.52M
Enterprise Value 489.69M
Income -54.42M
Sales —
FCF (ttm) -37.90M
Book/sh 1.88
Cash/sh 2.66
Employees 55
Insider 10d —
IPO Jul 27, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 37.07
PEG —
P/S —
P/B 4.33
P/C —
EV/EBITDA -8.81
EV/Sales —
Quick Ratio 27.63
Current Ratio 28.05
Debt/Eq 35.70
LT Debt/Eq —
EPS (ttm) -1.01
EPS next Y 0.22
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-13
Earnings (prior) 2026-05-14
ROA -23.64%
ROE -51.17%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 73.27M
Shs Float 56.78M
Insider Own 15.78%
Instit Own 59.72%
Short Float 25.18%
Short Ratio 6.46
Short Interest 14.16M
52W High 9.57
vs 52W High -14.79%
52W Low 4.35
vs 52W Low 87.47%
Beta -0.48
Impl. Vol. 1.65%
Rel Volume 0.56
Avg Volume 1.80M
Volume 1.02M
Target (mean) $19.62
Tgt Median $19.50
Tgt Low $9.00
Tgt High $29.00
# Analysts 8
Recom Strong_buy
Prev Close $8.67
Price $8.15
Change -5.94%
About

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$19.63
Mean price target
2. Current target
$8.13
Latest analyst target
3. DCF / Fair value
$-9.31
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.13
Low
$9.00
High
$29.00
Mean
$19.63

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-20 init Cantor Fitzgerald — → Overweight —
2026-03-18 main Citigroup Buy → Buy $26
2026-03-13 main Citigroup Buy → Buy $22
2026-03-13 main Canaccord Genuity Buy → Buy $25
2025-12-08 reit Stephens & Co. Overweight → Overweight $15
2025-11-21 main Freedom Broker Buy → Buy $14
2025-11-14 main Citigroup Buy → Buy $24
2025-10-28 init Stephens & Co. — → Overweight $15
2025-10-21 init LifeSci Capital — → Outperform $16
2025-09-29 reit HC Wainwright & Co. Buy → Buy $23
2025-09-03 down B of A Securities Buy → Neutral $7
2025-04-11 reit HC Wainwright & Co. Buy → Buy $19
2025-03-14 reit HC Wainwright & Co. Buy → Buy $19
2025-02-26 main Canaccord Genuity Buy → Buy $25
2025-02-26 reit HC Wainwright & Co. Buy → Buy $19
2025-02-20 init Citigroup — → Buy $25
2025-02-19 init Canaccord Genuity — → Buy $20
2025-02-07 init B of A Securities — → Buy $15
2024-12-18 reit HC Wainwright & Co. Buy → Buy $19
2024-11-18 reit HC Wainwright & Co. Buy → Buy $11
News
RSS: Latest CADL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-23 MANNING PAUL B. Director — 550,458 $5.45 $2,999,996
2025-07-28 NICHOLS WILLIAMS GARRETT Officer — 937 $1.29 $1,209
2025-07-28 NICHOLS WILLIAMS GARRETT Officer — 937 $6.98 $6,540
2025-06-30 NICHOLS WILLIAMS GARRETT Officer — 781 $1.29 $1,007
2025-06-30 NICHOLS WILLIAMS GARRETT Officer — 781 $5.04 $3,936
2025-06-25 PAPA JOSEPH C Director — 64,239 $4.67 $299,996
2025-06-25 MANNING PAUL B. Director — 1,070,663 $4.67 $4,999,996
2025-06-25 NABEL GARY J. Director — 5,353 $4.67 $24,999
2025-06-25 MARTELL CHRISTOPHER Director — 111,349 $4.67 $520,000
2025-06-25 TAK PAUL PETER Chief Executive Officer — 42,826 $4.67 $199,997
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
-100.00%
0.12
Operating Revenue
0.00
0.00
0.00
-100.00%
0.12
Operating Expense
48.18
+44.37%
33.37
-13.08%
38.39
+10.32%
34.80
Research And Development
30.50
+57.90%
19.31
-21.19%
24.51
+17.89%
20.79
Selling General And Administration
17.77
+26.41%
14.06
+1.24%
13.88
-1.24%
14.06
General And Administrative Expense
17.77
+26.41%
14.06
+1.24%
13.88
-1.24%
14.06
Salaries And Wages
7.64
+11.90%
6.83
-11.65%
7.73
+6.94%
7.23
Other Gand A
8.94
+52.99%
5.85
+33.01%
4.39
+3.12%
4.26
Other Operating Expenses
-0.09
—
—
-0.05
Total Expenses
48.18
+44.37%
33.37
-13.08%
38.39
+10.32%
34.80
Operating Income
-48.18
-44.37%
-33.37
+13.08%
-38.39
-10.72%
-34.67
Total Operating Income As Reported
-48.27
-44.63%
-33.37
+13.08%
-38.39
-10.57%
-34.72
EBITDA
-35.22
+32.40%
-52.10
-51.52%
-34.38
-110.84%
-16.31
Normalized EBITDA
-43.42
-38.73%
-31.30
+11.47%
-35.35
-8.18%
-32.68
Reconciled Depreciation
0.84
-14.65%
0.99
+3.13%
0.96
+23.39%
0.78
EBIT
-36.06
+32.07%
-53.09
-50.20%
-35.34
-106.86%
-17.09
Total Unusual Items
8.20
+139.41%
-20.80
-2253.42%
0.97
-94.10%
16.37
Total Unusual Items Excluding Goodwill
8.20
+139.41%
-20.80
-2253.42%
0.97
-94.10%
16.37
Net Income
-38.18
+30.80%
-55.18
-45.44%
-37.94
-101.87%
-18.79
Pretax Income
-38.18
+30.80%
-55.18
-45.44%
-37.94
-101.87%
-18.79
Net Non Operating Interest Income Expense
1.80
+278.88%
-1.00
-95.33%
-0.51
-4.90%
-0.49
Interest Expense Non Operating
2.12
+1.39%
2.09
-19.46%
2.60
+51.93%
1.71
Net Interest Income
1.80
+278.88%
-1.00
-95.33%
-0.51
-4.90%
-0.49
Interest Expense
2.12
+1.39%
2.09
-19.46%
2.60
+51.93%
1.71
Interest Income Non Operating
3.92
+260.50%
1.09
-47.81%
2.08
+70.85%
1.22
Interest Income
3.92
+260.50%
1.09
-47.81%
2.08
+70.85%
1.22
Other Income Expense
8.20
+139.41%
-20.80
-2253.42%
0.97
-94.10%
16.37
Gain On Sale Of Security
8.20
+139.41%
-20.80
-2253.42%
0.97
-94.10%
16.37
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-38.18
+30.80%
-55.18
-45.44%
-37.94
-101.87%
-18.79
Net Income From Continuing Operation Net Minority Interest
-38.18
+30.80%
-55.18
-45.44%
-37.94
-101.87%
-18.79
Net Income From Continuing And Discontinued Operation
-38.18
+30.80%
-55.18
-45.44%
-37.94
-101.87%
-18.79
Net Income Continuous Operations
-38.18
+30.80%
-55.18
-45.44%
-37.94
-101.87%
-18.79
Normalized Income
-46.38
-34.93%
-34.38
+11.64%
-38.91
-10.64%
-35.16
Net Income Common Stockholders
-38.18
+30.80%
-55.18
-45.44%
-37.94
-101.87%
-18.79
Diluted EPS
-0.72
+58.62%
-1.74
-32.82%
-1.31
-101.54%
-0.65
Basic EPS
-0.72
+58.62%
-1.74
-32.82%
-1.31
-101.54%
-0.65
Basic Average Shares
52.96
+67.19%
31.68
+9.47%
28.94
+0.39%
28.82
Diluted Average Shares
52.96
+67.19%
31.68
+9.47%
28.94
+0.39%
28.82
Diluted NI Availto Com Stockholders
-38.18
+30.80%
-55.18
-45.44%
-37.94
-101.87%
-18.79
Insurance And Claims
0.99
-16.84%
1.19
-25.61%
1.60
-33.01%
2.38
Rent And Landing Fees
0.19
+1.04%
0.19
+19.25%
0.16
-12.50%
0.18
Rent Expense Supplemental
0.19
+1.04%
0.19
+19.25%
0.16
-12.50%
0.18
Total Other Finance Cost
—
—
—
0.49
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
125.19
+17.15%
106.87
+159.38%
41.20
-46.97%
77.69
Current Assets
121.39
+16.94%
103.80
+182.10%
36.80
-48.85%
71.94
Cash Cash Equivalents And Short Term Investments
119.73
+16.64%
102.65
+189.88%
35.41
-49.45%
70.06
Cash And Cash Equivalents
119.73
+16.64%
102.65
+189.88%
35.41
-49.45%
70.06
Prepaid Assets
—
—
—
—
Other Current Assets
1.66
+44.17%
1.15
-16.91%
1.38
-26.66%
1.89
Total Non Current Assets
3.81
+24.30%
3.06
-30.47%
4.40
-23.36%
5.75
Net PPE
3.30
+20.86%
2.73
-32.05%
4.02
-26.61%
5.48
Gross PPE
6.86
+18.11%
5.81
-4.94%
6.11
-7.54%
6.61
Accumulated Depreciation
-3.56
-15.67%
-3.08
-47.25%
-2.09
-85.03%
-1.13
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.39
+58.20%
0.24
-1.21%
0.25
+2.92%
0.24
Construction In Progress
—
—
—
—
Other Properties
3.47
+41.16%
2.46
-10.85%
2.75
-16.82%
3.31
Leases
3.01
-3.25%
3.11
+0.00%
3.11
+1.70%
3.06
Other Non Current Assets
0.50
+52.89%
0.33
-13.87%
0.38
+43.61%
0.27
Total Liabilities Net Minority Interest
73.27
+80.75%
40.54
+42.46%
28.46
-5.07%
29.98
Current Liabilities
9.00
-76.03%
37.53
+164.59%
14.18
+152.61%
5.62
Payables And Accrued Expenses
8.46
+58.19%
5.35
+11.97%
4.78
-6.37%
5.10
Payables
1.13
+376.37%
0.24
-43.84%
0.42
+11.05%
0.38
Accounts Payable
1.13
+376.37%
0.24
-43.84%
0.42
+11.05%
0.38
Current Accrued Expenses
7.33
+43.44%
5.11
+17.38%
4.36
-7.77%
4.72
Current Debt And Capital Lease Obligation
0.45
-95.75%
10.46
+11.22%
9.41
+1927.16%
0.46
Current Debt
—
9.89
+11.27%
8.89
—
Other Current Borrowings
—
9.89
+11.27%
8.89
—
Current Capital Lease Obligation
0.45
-21.38%
0.57
+10.33%
0.51
+10.56%
0.46
Other Current Liabilities
0.09
-99.59%
21.72
—
0.05
Total Non Current Liabilities Net Minority Interest
64.28
+2035.42%
3.01
-78.91%
14.27
-41.42%
24.36
Long Term Debt And Capital Lease Obligation
48.59
+1514.25%
3.01
-77.46%
13.36
-40.20%
22.34
Long Term Debt
47.13
+1710.60%
2.60
-78.98%
12.38
-40.61%
20.85
Long Term Capital Lease Obligation
1.46
+258.48%
0.41
-58.17%
0.97
-34.52%
1.49
Non Current Deferred Liabilities
0.09
0.00
0.00
-100.00%
0.14
Non Current Deferred Revenue
0.09
0.00
0.00
-100.00%
0.14
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
51.92
-21.72%
66.33
+420.42%
12.74
-73.29%
47.71
Common Stock Equity
51.92
-21.72%
66.33
+420.42%
12.74
-73.29%
47.71
Capital Stock
0.55
+17.27%
0.47
+61.72%
0.29
+0.00%
0.29
Common Stock
0.55
+17.27%
0.47
+61.72%
0.29
+0.00%
0.29
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
55.02
+17.23%
46.93
+60.65%
29.21
+0.59%
29.04
Ordinary Shares Number
54.90
+17.28%
46.81
+60.91%
29.09
+0.59%
28.92
Treasury Shares Number
0.12
+0.00%
0.12
+0.00%
0.12
+0.00%
0.12
Additional Paid In Capital
282.21
+9.17%
258.51
+72.42%
149.93
+2.02%
146.96
Retained Earnings
-230.39
-19.87%
-192.21
-40.27%
-137.03
-38.29%
-99.09
Treasury Stock
0.45
+0.00%
0.45
+0.00%
0.45
+0.00%
0.45
Total Equity Gross Minority Interest
51.92
-21.72%
66.33
+420.42%
12.74
-73.29%
47.71
Total Capitalization
99.05
+43.70%
68.93
+174.32%
25.13
-63.35%
68.56
Working Capital
112.39
+69.58%
66.28
+193.08%
22.61
-65.91%
66.33
Invested Capital
99.05
+25.66%
78.83
+131.70%
34.02
-50.38%
68.56
Total Debt
49.03
+264.00%
13.47
-40.82%
22.76
-0.17%
22.80
Capital Lease Obligations
1.90
+95.68%
0.97
-34.52%
1.49
-23.79%
1.95
Net Tangible Assets
51.92
-21.72%
66.33
+420.42%
12.74
-73.29%
47.71
Tangible Book Value
51.92
-21.72%
66.33
+420.42%
12.74
-73.29%
47.71
Derivative Product Liabilities
15.60
0.00
-100.00%
0.92
-51.33%
1.88
Line Of Credit
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-38.31
-41.77%
-27.02
+21.09%
-34.24
-8.99%
-31.42
Cash Flow From Continuing Operating Activities
-38.31
-41.77%
-27.02
+21.09%
-34.24
-8.99%
-31.42
Net Income From Continuing Operations
-38.18
+30.80%
-55.18
-45.44%
-37.94
-101.87%
-18.79
Depreciation Amortization Depletion
0.84
-14.65%
0.99
+3.13%
0.96
+23.39%
0.78
Depreciation
0.84
-14.65%
0.99
+3.13%
0.96
+23.39%
0.78
Depreciation And Amortization
0.84
-14.65%
0.99
+3.13%
0.96
+23.39%
0.78
Other Non Cash Items
0.82
+23.53%
0.66
-0.45%
0.67
+13.07%
0.59
Stock Based Compensation
3.82
-28.14%
5.31
+71.85%
3.09
+33.98%
2.31
Asset Impairment Charge
0.09
+119.51%
0.04
-89.49%
0.39
0.00
Operating Gains Losses
-7.89
-137.94%
20.80
+2445.21%
-0.89
+94.58%
-16.37
Gain Loss On Investment Securities
-8.20
-139.41%
20.80
+2253.42%
-0.97
+94.10%
-16.37
Gain Loss On Sale Of PPE
0.31
0.00
-100.00%
0.08
0.00
Change In Working Capital
2.19
+533.82%
0.35
+165.90%
-0.53
-839.44%
0.07
Change In Prepaid Assets
-0.51
-317.09%
0.23
-53.48%
0.50
+20.91%
0.42
Change In Payables And Accrued Expense
3.06
+434.27%
0.57
+323.44%
-0.26
-592.31%
0.05
Change In Accrued Expense
2.25
+197.75%
0.76
+351.50%
-0.30
-123.79%
1.26
Change In Payable
0.80
+533.51%
-0.18
-511.11%
0.04
+103.71%
-1.21
Change In Account Payable
0.80
+533.51%
-0.18
-511.11%
0.04
+103.71%
-1.21
Change In Other Working Capital
0.18
—
-0.19
-386.57%
0.07
Change In Other Current Assets
-0.02
-145.28%
0.05
+145.69%
-0.12
0.00
Change In Other Current Liabilities
-0.51
+0.78%
-0.51
-10.56%
-0.46
+0.00%
-0.46
Investing Cash Flow
-0.56
-3400.00%
-0.02
+94.29%
-0.28
+78.41%
-1.30
Cash Flow From Continuing Investing Activities
-0.56
-3400.00%
-0.02
+94.29%
-0.28
+78.41%
-1.30
Net PPE Purchase And Sale
-0.56
-3400.00%
-0.02
+94.29%
-0.28
+78.41%
-1.30
Purchase Of PPE
-0.59
-3568.75%
-0.02
+96.50%
-0.46
+64.76%
-1.30
Sale Of PPE
0.03
0.00
-100.00%
0.18
0.00
Capital Expenditure
-0.59
-3568.75%
-0.02
+96.50%
-0.46
+64.76%
-1.30
Net Investment Purchase And Sale
—
—
—
—
Purchase Of Investment
—
—
—
—
Sale Of Investment
—
—
—
—
Financing Cash Flow
56.10
-40.50%
94.28
+78017.36%
-0.12
-100.61%
19.97
Cash Flow From Continuing Financing Activities
56.10
-40.50%
94.28
+78017.36%
-0.12
-100.61%
19.97
Net Issuance Payments Of Debt
36.21
+495.04%
-9.17
0.00
-100.00%
19.91
Issuance Of Debt
47.95
0.00
0.00
-100.00%
19.91
Repayment Of Debt
-11.73
-27.99%
-9.17
0.00
—
Long Term Debt Issuance
47.95
0.00
0.00
-100.00%
19.91
Long Term Debt Payments
-11.73
-27.99%
-9.17
0.00
—
Net Long Term Debt Issuance
36.21
+495.04%
-9.17
0.00
-100.00%
19.91
Net Common Stock Issuance
19.37
-80.97%
101.76
0.00
0.00
Proceeds From Stock Option Exercised
0.52
-69.45%
1.69
0.00
-100.00%
0.06
Net Other Financing Charges
—
—
-0.12
—
Changes In Cash
17.23
-74.38%
67.24
+294.09%
-34.65
-171.90%
-12.74
Beginning Cash Position
102.92
+188.46%
35.68
-49.26%
70.32
-15.34%
83.07
End Cash Position
120.15
+16.74%
102.92
+188.46%
35.68
-49.26%
70.32
Free Cash Flow
-38.90
-43.86%
-27.04
+22.08%
-34.70
-6.07%
-32.72
Interest Paid Supplemental Data
1.28
-28.69%
1.79
-16.43%
2.15
+86.46%
1.15
Income Tax Paid Supplemental Data
—
—
0.00
-100.00%
0.18
Common Stock Issuance
19.37
-80.97%
101.76
0.00
0.00
Issuance Of Capital Stock
19.37
-80.97%
101.76
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category